Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Endologix investigates new Powerlink graft in large diameter aneurysm necks:

This article was originally published in Clinica

Executive Summary

Seeking to broaden the market for its Powerlink stent graft for treating abdominal aortic aneurysm (AAA), Endologix has begun a US clinical trial to test a modified version the device designed to treat aneurysms with larger neck diameters. If approved, the new device could become the first endoluminal stent graft (ELG) for use in aneurysms with neck diameters up to 32mm, according to the Irvine, California firm, which has already received FDA approval to sell the original form of the product. "The Powerlink 34mm system has the ability to expand the universe of AAA patients suitable for minimally invasive ELGs as approximately 5-10% of those evaluated are excluded due to a large aortic neck diameter," said Paul McCormick, Endologix' president and CEO.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT056562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel